Cite
HARVARD Citation
Kalin, A. et al. (n.d.). A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies. Amyotrophic lateral sclerosis and frontotemporal degeneration. pp. 71-79. [Online].